Meeting
2015 ASCO Annual Meeting
Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC).
Authors
D. Ross Camidge
University of Colorado Cancer Center, Aurora, CO
D. Ross Camidge , Lyudmila Bazhenova , Ravi Salgia , Corey J. Langer , Kathryn A. Gold , Rafael Rosell , Alice Tsang Shaw , Glen J. Weiss , Narayana I. Narasimhan , David J. Dorer , Victor M. Rivera , Timothy Piers Clackson , Maureen G Conlan , David Kerstein , Frank G. Haluska , Scott N. Gettinger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01449461
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8062)
DOI
10.1200/jco.2015.33.15_suppl.8062
Abstract #
8062
Poster Bd #
385
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC).
First Author: Scott N. Gettinger
Poster
2022 ASCO Annual Meeting
A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non–small cell lung cancer (IFCT-2101 MASTERPROTOCOL ALK).
First Author: Michaël Duruisseaux
Poster
2021 ASCO Annual Meeting
Outcomes of first, second, and third-generation anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer brain metastases (NSCLCBM).
First Author: Vineeth Tatineni
Poster
2019 ASCO Annual Meeting
Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)−positive, advanced non–small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.
First Author: Edward S. Kim